We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 28 juli 2017

The Lancet: [News] Tobacco companies flout anti-tobacco laws in India

[News] Tobacco companies flout anti-tobacco laws in India
Smoking remains one of the highest risks to health in India, leading to a death toll of almost 1 million people per year. According to WHO estimates, tobacco-related diseases cost the country about US$16 billion annually. However, the number of people who smoke still proliferates.
Read more

[News] Redefining the molecular substructure of medulloblastoma
An international research consortium has uncovered the genetic causes of the consensus molecular subgroups of medulloblastoma, which display distinct transcriptional and genetic alterations, and differential epigenetic signatures. Notably, subgroup-specific driver alterations of the previously poorly characterised group 3 and group 4 subgroups were unravelled.
Read more

[Corrections] Correction to 2016; 17: 727–37
Duchesne GM, Woo HH, Bassett JK, et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol 2016; 17: 727–37—In Figure 1 of this Article, the number of patients who withdrew after randomisation should have been 1 in the delayed ADT group and 2 in the immediate ADT group. This correction has been made to the online version as of July 28, 2017.
Read more

[Comment] New perspectives for TAS-102: TASK successful?
The US Food and Drug Administration and European Medicines Agency have granted approval to TAS-102 for the treatment of refractory metastatic colorectal cancer.1,2 In The Lancet Oncology, Yasutoshi Kuboki and colleagues report on the results of C-TASK FORCE,3 a phase 1/2 study on the combination of TAS-102 with bevacizumab. The rationale for this study was sound and strong. Phosphorylated trifluridine concentration and tumour growth inhibition are increased with the combination of TAS-102 and bevacizumab compared with either drug alone.
Read more

[Articles] Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Immediate use of androgen-deprivation therapy was associated with early detriments in specific hormone-treatment-related symptoms, but with no other demonstrable effect on overall functioning or health-related quality of life. This evidence can be used to help decision making about treatment initiation for men at this disease stage.
Read more